Articles & Whitepapers
People living with frontotemporal dementia, or FTD, are commonly misdiagnosed with psychiatric disorders or Alzheimer’s disease and other causes of dementia, such as Parkinson’s disease and vascular dementia. While frontotemporal dementia and Alzheimer’s disease can both cause dementia, there are distinct differences in impacted regions of the brain and, consequently, ...
Health research is very important for improving health care for all. As we mentioned in a previous article, What is Health Research?, this type of research helps medical researchers understand ...
TEL AVIV & WENDELSHEIM, Germany--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG's lead compound ...
Oligomerix Presents Data on Lead Program at Clinical Trials on Alzheimer’s Disease (CTAD) Conference and Society for Neuroscience Meeting
Oligomerix Announces Issuance of Key U.S. Patent for Lead Tau-Targeting Candidate OLX-07010 to Treat Neurodegenerative Diseases
Oligomerix Announces Series B Extension Raise of $2.7 Million to Support Phase 1 Clinical Development
Equipment & Solutions
The accumulation of amyloid-beta protein in the cerebral cortex in Alzheimer's disease (AD) is responsible for plaque formation. Amyloid-beta is produced by proteolytic cleavage of amyloid precursor protein (APP), mediated by the enzymes beta- and gamma-secretase. The cleavage reaction produces a number of peptides, ranging from 36 to 43 amino acids in length. These antibodies can detect ...